Recent News

• 03.30.2026 - Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
• 03.09.2026 - Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
• 03.04.2026 - Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
• 03.02.2026 - Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
• 01.30.2026 - Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
• 01.21.2026 - Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026

Recent Filings

• 03.26.2026 - EX-99.1 EX-99.1
• 03.26.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.19.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.19.2026 - EX-99.1 EX-99.1
• 03.16.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.16.2026 - EX-99.1 EX-99.1
• 03.09.2026 - EX-99.1 EX-99.1
• 03.09.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.04.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.04.2026 - EX-99.1 EX-99.1